Abstract
Urinary incontinence is estimated to affect more than 30 million people in the developed world. However, while this disorder is treatable and often curable in most individuals, the efficacy and tolerability of currently available therapeutic agents is far from optimal. Tolterodine * is a new muscarinic antagonist specifically developed for the treatment of urinary urge incontinence and other symptoms of detrusor overactivity. In this week’s issue, Inpharma ® maps the progress of this interesting compound in preclinical studies and preliminary phase II clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
